Alaunos Therapeutics Inc
Alaunos Therapeutics Inc logo
TCRT

Alaunos Therapeutics Inc (TCRT)

$1.737.98%

Market closed
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$1.61
Day's Range
$1.8699
$0.4053
52-Week Range
$4.01
1 month return28.51%
3 month return57.27%
1 year return109.65%
5 year return109.65%

Company Information

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
OrganizationAlaunos Therapeutics Inc
Employees105
CEO
IndustryHealth Technology

Analyst Recommendation

based on 12 analysts ratings

Buy
75%
Buy
25%
Hold
0%
Sell

Based on 12 Wall street analysts offering stock ratings for Alaunos Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 44.51%

Current

$1.73

Target

$2.5

Recommendation Trend

Based on 12 analyst

Current1M Ago3M Ago
Buy
9
8
8
Hold
3
3
4
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
374.0M
Book Value
$0.19
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.31
Wall Street Target Price
4.2

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
9.31
Enterprise Value
341.5M
Enterprise Value/Revenue
858.06
Enterprise Value/Ebitda
-6.99

Technicals

Beta
0.12
50 Day MA
2.04
200 Day MA
1.14

Institutional Holdings

MSD Partners, L.P.

7.01%

Discovery Capital Management LLC

6.48%

Vanguard Group Inc

4.3%

State Street Corporation

2.41%

Goldman Sachs Group Inc

2.11%

JPMorgan Chase & Co

1.52%

Discover more

Frequently Asked Questions

What is Alaunos Therapeutics Inc share price today?

Can Indians buy Alaunos Therapeutics Inc shares?

How can I buy Alaunos Therapeutics Inc shares from India?

Can Fractional shares of Alaunos Therapeutics Inc be purchased?

What are the documents required to start investing in Alaunos Therapeutics Inc stocks?

What are today’s High and Low prices of Alaunos Therapeutics Inc?

What are today’s traded volumes of Alaunos Therapeutics Inc?

What is today’s market capitalisation of Alaunos Therapeutics Inc?

What is the 52 Week High and Low Range of Alaunos Therapeutics Inc?

How much percentage Alaunos Therapeutics Inc is down from its 52 Week High?

How much percentage Alaunos Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Alaunos Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Alaunos Therapeutics Inc?